An investment fund is seeking an order requiring Dendreon to perform its obligations under the agreement and pay the $9 million plus accrued interest, along with attorney fees and costs.
Investment Fund Sues Biopharma Company, Claiming $9 Million Unpaid in Contract Breach
Leave a Reply